Odefsey (Emtricitabine, Tenofovir Alafenamide, Rilpivirine)

Odefsey is a fixed‑dose combination antiretroviral indicated for the treatment of HIV‑1 infection in patients who have previously achieved viral suppression on a stable regimen.

• HIV‑1 infection (treatment‑experienced): provides a complete, once‑daily regimen that maintains viral suppression.
• HIV‑1 infection (maintenance therapy): simplifies therapy by combining three agents in one tablet, improving adherence.
• HIV‑1 infection (adults and adolescents ≥35 kg): offers a single‑pill option that meets guideline‑recommended backbone and integrase‑strand‑inhibitor‑free regimens.

• The three components act at different stages of the HIV replication cycle: emtricitabine and tenofovir alafenamide are nucleos(t)ide reverse‑transcriptase inhibitors that block viral DNA synthesis, while rilpivirine is a non‑nucleoside reverse‑transcriptase inhibitor that binds to a distinct site on the reverse‑transcriptase enzyme, preventing transcription of viral RNA.

Adverse reactions reported with Odefsey are generally mild to moderate and reflect the pharmacology of its components.

Common Side Effects

• Nausea: mild, transient gastrointestinal upset.
• Headache: occasional, resolves without intervention.
• Diarrhoea: loose stools, usually self‑limiting.
• Fatigue: general tiredness reported by some patients.
• Insomnia: difficulty falling or staying asleep.
• Rash: mild skin erythema.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: including Stevens‑Johnson syndrome.
• Hepatic impairment: elevated transaminases or liver injury.
• Lactic acidosis: rare metabolic complication.
• Severe depression or suicidal ideation: reported in a minority of patients.
• Renal toxicity: rare cases of kidney function decline.
• QT‑interval prolongation: uncommon cardiac effect.

When prescribing Odefsey, clinicians should consider several safety aspects.

• Baseline laboratory testing: obtain hepatic, renal and viral load measurements before initiation.
• Drug‑resistance testing: ensure the virus is susceptible to the components.
• Co‑administration with acid‑reducing agents: may reduce rilpivirine exposure; monitor efficacy.
• Pregnancy and lactation: weigh benefits against potential risks; consult guidelines.
• Concomitant medications: review for interactions that may affect plasma levels.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Odefsey interacts with several drug classes; awareness of the interaction potential helps maintain therapeutic effectiveness.

Major Interactions (Avoid)

• Antacids containing aluminium or magnesium: markedly reduce rilpivirine absorption.
• Proton pump inhibitors (e.g., omeprazole): decrease rilpivirine exposure and may compromise viral suppression.
• Rifampicin and other strong CYP3A inducers: lower plasma concentrations of rilpivirine.

Moderate Interactions (Monitor Closely)

• H2‑receptor antagonists (e.g., ranitidine): may modestly reduce rilvivirine levels.
• Lipid‑lowering agents (statins): increased risk of statin‑related myopathy.
• Contraceptive hormones: potential reduction in hormonal efficacy.
• Warfarin: possible alteration of INR values.
• Antifungal azoles (e.g., ketoconazole): may increase rilpivirine concentrations.